个人中心 - 老虎社区

RyanYe

IP属地：未知

帖子 · 6帖子 · 6
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- RyanYeRyanYe
  ·2021-10-23
  所以商品不是疫情恢复好的国家生产的。瞎说
  高盛：旧经济的“复仇”
  在各国努力从化石燃料转向更清洁能源之际，全球能源供应的脆弱性通过这次疫情暴露了出来。高盛全球大宗商品研究主管Jeffff Currie周四在英国金融时报撰文称：人们很容易将当前“旧经济”中的供
  高盛：旧经济的“复仇”
  2,961 评论
  点赞
  分享
  举报
- RyanYeRyanYe
  ·2021-10-16
  $SOS Limited(SOS)$区块链跌，你也跌，区块链涨，你横盘。干
  3,072 评论
  2
  分享
  举报
- RyanYeRyanYe
  ·2021-10-03
  骗子吧，现实宇宙还没搞清楚
  非常抱歉，此主贴已删除
  2,820 评论
  5
  分享
  举报
- RyanYeRyanYe
  ·2021-09-16
  嘿，真香
  非常抱歉，此主贴已删除
  3,568 评论
  点赞
  分享
  举报
- RyanYeRyanYe
  ·2021-09-09
  中奖了
  U.S. FDA declines emergency use approval for Humanigen's COVID-19 drug
  Sept 9 (Reuters) - The U.S. Food and Drug Administration declined Humanigen Inc's request for emerge
  U.S. FDA declines emergency use approval for Humanigen's COVID-19 drug
  4,447 评论
  点赞
  分享
  举报
- RyanYeRyanYe
  ·2021-09-03
  $洪恩教育(IH)$现在封杀补课，为啥不投快乐教育？
  4,673 1
  2
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3494524945898080","uuid":"3494524945898080","gmtCreate":1628248605956,"gmtModify":1629945275008,"name":"RyanYe","pinyin":"ryanye","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/bbd18b884a4e5ccdb7802012080e0305","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":28,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.13","exceedPercentage":"80.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.13","exceedPercentage":"93.28%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":858982733,"gmtCreate":1634963410729,"gmtModify":1634963410729,"author":{"id":"3494524945898080","authorId":"3494524945898080","name":"RyanYe","avatar":"https://static.tigerbbs.com/bbd18b884a4e5ccdb7802012080e0305","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494524945898080","authorIdStr":"3494524945898080"},"themes":[],"htmlText":"所以商品不是疫情恢复好的国家生产的。瞎说","listText":"所以商品不是疫情恢复好的国家生产的。瞎说","text":"所以商品不是疫情恢复好的国家生产的。瞎说","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/858982733","repostId":"2177824413","repostType":4,"repost":{"id":"2177824413","kind":"highlight","pubTimestamp":1634909236,"share":"https://ttm.financial/m/news/2177824413?lang=&edition=full","pubTime":"2021-10-22 21:27","market":"us","language":"zh","title":"高盛：旧经济的“复仇”","url":"https://stock-news.laohu8.com/highlight/detail?id=2177824413","media":"华尔街见闻","summary":"在各国努力从化石燃料转向更清洁能源之际，全球能源供应的脆弱性通过这次疫情暴露了出来。\n高盛全球大宗商品研究主管Jeffff Currie周四在英国金融时报撰文称：\n\n 人们很容易将当前“旧经济”中的供","content":"<p>在各国努力从化石燃料转向更清洁能源之际，全球能源供应的脆弱性通过这次疫情暴露了出来。</p>\n<p><a href=\"https://laohu8.com/S/GS\">高盛</a>全球大宗商品研究主管Jeffff Currie周四在英国金融时报撰文称：</p>\n<blockquote>\n 人们很容易将当前“旧经济”中的供应短缺——从能源到其他基础材料，甚至<a href=\"https://laohu8.com/S/000061\">农产品</a>，归咎于主要由疫情造成的一系列暂时中断，但除了少数劳动力短缺之外，这些供应瓶颈与疫情几乎没有关系。\n</blockquote>\n<blockquote>\n 相反， \n <b>今天大宗商品危机的根源可以追溯到金融危机的余波，以及随后十年的回报率下降和旧经济的长期投资不足。</b>\n</blockquote>\n<h2>旧经济的“复仇”</h2>\n<p>Jeffff Currie在文章中写道：</p>\n<p>为应对2008年后的经济停滞，政策制定者通过央行量化宽松来支持复苏。结果是：收入较低的家庭面临着实际工资增长缓慢、经济不安全、信贷限制收紧以及越来越难以负担的昂贵实物资产。另一方面，高收入家庭则受益于量化宽松带来的金融资产通胀。</p>\n<p>这种结果上的差异严重打击了旧经济。高收入家庭可能掌握着美元，但低收入家庭决定着商品需求量，因为他们的数量更为庞大，且更倾向于消费实物商品而不是服务。</p>\n<p>随着大宗商品需求的减少，旧经济部门的回报也随之减少。较低的回报导致长周期的旧经济资本支出减少（传统上需要有5-10年的充足需求），而有利于技术等短周期“新经济”领域的投资。</p>\n<p>事实上，旧经济已经是过度建设、负债累累和污染过度。虽然旧经济仅占全球GDP的35%左右，但至少占到企业总损失的70%，非金融债务的90%，以及碳排放的80%。这也难怪投资者更喜欢大型科技公司，而不是石油和铜。</p>\n<p>尤其是2015年油价暴跌后，市场受够了财富的毁灭，对旧经济的投资大幅下降。</p>\n<p>根据Rystad Energy的数据，2010年至2015年，全球石油和天然气勘探支出（不包括页岩气）平均每年约为1000亿美元，但在原油价格暴跌后的几年里，该数据平均下降至500亿美元左右。</p>\n<p>与此同时，随着气候变化成为人们最关心的问题，投资者更加关注ESG（环境、社会和治理问题），进一步限制了对旧经济的投资。</p>\n<p>由此阻碍了大宗商品产能的增长。特别是在油气行业，投资者出于ESG的原因进行剥离，加剧了本已日益严重的投资不足问题。</p>\n<p>随着各国从疫情后进入复苏，这些供应限制的严重性得到突显，暴露出旧经济有多么捉襟见肘。</p>\n<h2>新经济的增长速度不足以填补缺口</h2>\n<p>在过去20年里，风力、<a href=\"https://laohu8.com/S/000591\">太阳能</a>发电厂和其他可再生能源的发展速度加快，因为规模经济降低了技术成本，与基于化石燃料的发电相比更具竞争力。</p>\n<p>国际可再生能源署(IRENA)的数据显示，2020年，不包括水力发电和抽水蓄能在内的全球可再生能源装机容量超过了150万兆瓦，而2000年还不到5.5万兆瓦。</p>\n<p>在美国和欧洲，在政府补贴和其他旨在减少煤炭使用的政策的帮助下，可再生能源获得了一定的市场份额。2019年疫情爆发前，美国可再生能源消费量自1885年以来首次超过煤炭消费量。这种增长预计将继续下去。</p>\n<p>国际能源署的数据显示，2020年全球可再生能源发电量增加了28万兆瓦，较2019年增长了45%。该机构将这一增长率称为“新常态”，并预计今明两年将保持类似的增长率。</p>\n<p><b>尽管如此，化石燃料仍占全球发电的大部分。根据IRENA的数据，2019年可再生能源仍只占全球发电量的26%。</b></p>\n<p>某种程度上，风能和水力发电等可再生资源的供应低于预期，进一步推高了对化石燃料的需求。</p>\n<p><b>而这其中的困难在于：试图加快向清洁能源过渡的政府发现，这需要大量投资，并可能遇到意想不到的障碍。</b></p>\n<p>在美国，加州正按照州法律的要求，让大量化石燃料发电厂退出市场，以帮助其在 2045 年之前实现电网脱碳。</p>\n<p>加州公共事业委员会已下令各公用事业公司购买数量空前的可再生能源、电池存储和其他无碳资源，以填补这一缺口，并跟上未来几年的增长：超过14000兆瓦，约为该州夏季峰值需求的三分之一。</p>\n<p>尽管两家公司目前都在正轨上，但加州能源委员会和该州电网运营商最近表示，他们担心这些收购可能不足以防止未来夏季的电力短缺。该州还计划在2025年前淘汰最后一座核电站 Diablo Canyon，该核电站提供该州近10%的电力。</p>\n<p>今年夏天，森林大火中断了电力传输，严重的干旱减少了整个西部的水力发电，包括胡佛大坝。该州电网运营商多次呼吁居民节约用电，并采取紧急措施购买额外供应，该州最近还在发电厂增加了四台临时天然气发电机，这才勉强避免了轮流限电。</p>\n<h2>新的大宗商品超级周期即将到来</h2>\n<p>由于疫情后市场对商品的需求仍在激增，而随着基础设施老化和投资减少，旧经济供应和交付大宗商品及其制成品的能力也随之下降，与此同时，新经济的增长速度不足以填补缺口。</p>\n<p>在这种背景下，正如Jeffff Currie所认为的：</p>\n<p>金融体系存在连锁反应，对于一个紧绷的系统而言，较小的、频繁的冲击产生的持续影响会产生一种紧急现象，即短暂的冲击导致持续的实物价格通胀——我们今天看到的就是这种通胀的开始。</p>\n<p>这就是旧经济的报复将留下印记的地方。大宗商品价格压力时期将再次出现。</p>\n<p>同时，如果要实现政策制定者广泛繁荣和大规模建设绿色基础设施的目标，大宗商品价格将需要大幅上涨，以提供投资动机。</p>\n<p>这是因为绿色能源转型的内在复杂性，以及需要弥补长期资本支出项目中不断增长的风险。</p>\n<p>正如我们一年前所说的那样，一个新的大宗商品超级周期即将到来。</p>","source":"wallstreetcn_api","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛：旧经济的“复仇”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛：旧经济的“复仇”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-22 21:27 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3643057><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>在各国努力从化石燃料转向更清洁能源之际，全球能源供应的脆弱性通过这次疫情暴露了出来。\n高盛全球大宗商品研究主管Jeffff Currie周四在英国金融时报撰文称：\n\n 人们很容易将当前“旧经济”中的供应短缺——从能源到其他基础材料，甚至农产品，归咎于主要由疫情造成的一系列暂时中断，但除了少数劳动力短缺之外，这些供应瓶颈与疫情几乎没有关系。\n\n\n 相反， \n 今天大宗商品危机的根源可以追溯到金融危机...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3643057\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca","relate_stocks":{"GS":"高盛"},"source_url":"https://wallstreetcn.com/articles/3643057","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177824413","content_text":"在各国努力从化石燃料转向更清洁能源之际，全球能源供应的脆弱性通过这次疫情暴露了出来。\n高盛全球大宗商品研究主管Jeffff Currie周四在英国金融时报撰文称：\n\n 人们很容易将当前“旧经济”中的供应短缺——从能源到其他基础材料，甚至农产品，归咎于主要由疫情造成的一系列暂时中断，但除了少数劳动力短缺之外，这些供应瓶颈与疫情几乎没有关系。\n\n\n 相反， \n 今天大宗商品危机的根源可以追溯到金融危机的余波，以及随后十年的回报率下降和旧经济的长期投资不足。\n\n旧经济的“复仇”\nJeffff Currie在文章中写道：\n为应对2008年后的经济停滞，政策制定者通过央行量化宽松来支持复苏。结果是：收入较低的家庭面临着实际工资增长缓慢、经济不安全、信贷限制收紧以及越来越难以负担的昂贵实物资产。另一方面，高收入家庭则受益于量化宽松带来的金融资产通胀。\n这种结果上的差异严重打击了旧经济。高收入家庭可能掌握着美元，但低收入家庭决定着商品需求量，因为他们的数量更为庞大，且更倾向于消费实物商品而不是服务。\n随着大宗商品需求的减少，旧经济部门的回报也随之减少。较低的回报导致长周期的旧经济资本支出减少（传统上需要有5-10年的充足需求），而有利于技术等短周期“新经济”领域的投资。\n事实上，旧经济已经是过度建设、负债累累和污染过度。虽然旧经济仅占全球GDP的35%左右，但至少占到企业总损失的70%，非金融债务的90%，以及碳排放的80%。这也难怪投资者更喜欢大型科技公司，而不是石油和铜。\n尤其是2015年油价暴跌后，市场受够了财富的毁灭，对旧经济的投资大幅下降。\n根据Rystad Energy的数据，2010年至2015年，全球石油和天然气勘探支出（不包括页岩气）平均每年约为1000亿美元，但在原油价格暴跌后的几年里，该数据平均下降至500亿美元左右。\n与此同时，随着气候变化成为人们最关心的问题，投资者更加关注ESG（环境、社会和治理问题），进一步限制了对旧经济的投资。\n由此阻碍了大宗商品产能的增长。特别是在油气行业，投资者出于ESG的原因进行剥离，加剧了本已日益严重的投资不足问题。\n随着各国从疫情后进入复苏，这些供应限制的严重性得到突显，暴露出旧经济有多么捉襟见肘。\n新经济的增长速度不足以填补缺口\n在过去20年里，风力、太阳能发电厂和其他可再生能源的发展速度加快，因为规模经济降低了技术成本，与基于化石燃料的发电相比更具竞争力。\n国际可再生能源署(IRENA)的数据显示，2020年，不包括水力发电和抽水蓄能在内的全球可再生能源装机容量超过了150万兆瓦，而2000年还不到5.5万兆瓦。\n在美国和欧洲，在政府补贴和其他旨在减少煤炭使用的政策的帮助下，可再生能源获得了一定的市场份额。2019年疫情爆发前，美国可再生能源消费量自1885年以来首次超过煤炭消费量。这种增长预计将继续下去。\n国际能源署的数据显示，2020年全球可再生能源发电量增加了28万兆瓦，较2019年增长了45%。该机构将这一增长率称为“新常态”，并预计今明两年将保持类似的增长率。\n尽管如此，化石燃料仍占全球发电的大部分。根据IRENA的数据，2019年可再生能源仍只占全球发电量的26%。\n某种程度上，风能和水力发电等可再生资源的供应低于预期，进一步推高了对化石燃料的需求。\n而这其中的困难在于：试图加快向清洁能源过渡的政府发现，这需要大量投资，并可能遇到意想不到的障碍。\n在美国，加州正按照州法律的要求，让大量化石燃料发电厂退出市场，以帮助其在 2045 年之前实现电网脱碳。\n加州公共事业委员会已下令各公用事业公司购买数量空前的可再生能源、电池存储和其他无碳资源，以填补这一缺口，并跟上未来几年的增长：超过14000兆瓦，约为该州夏季峰值需求的三分之一。\n尽管两家公司目前都在正轨上，但加州能源委员会和该州电网运营商最近表示，他们担心这些收购可能不足以防止未来夏季的电力短缺。该州还计划在2025年前淘汰最后一座核电站 Diablo Canyon，该核电站提供该州近10%的电力。\n今年夏天，森林大火中断了电力传输，严重的干旱减少了整个西部的水力发电，包括胡佛大坝。该州电网运营商多次呼吁居民节约用电，并采取紧急措施购买额外供应，该州最近还在发电厂增加了四台临时天然气发电机，这才勉强避免了轮流限电。\n新的大宗商品超级周期即将到来\n由于疫情后市场对商品的需求仍在激增，而随着基础设施老化和投资减少，旧经济供应和交付大宗商品及其制成品的能力也随之下降，与此同时，新经济的增长速度不足以填补缺口。\n在这种背景下，正如Jeffff Currie所认为的：\n金融体系存在连锁反应，对于一个紧绷的系统而言，较小的、频繁的冲击产生的持续影响会产生一种紧急现象，即短暂的冲击导致持续的实物价格通胀——我们今天看到的就是这种通胀的开始。\n这就是旧经济的报复将留下印记的地方。大宗商品价格压力时期将再次出现。\n同时，如果要实现政策制定者广泛繁荣和大规模建设绿色基础设施的目标，大宗商品价格将需要大幅上涨，以提供投资动机。\n这是因为绿色能源转型的内在复杂性，以及需要弥补长期资本支出项目中不断增长的风险。\n正如我们一年前所说的那样，一个新的大宗商品超级周期即将到来。","news_type":1,"symbols_score_info":{"GS":0.9}},"isVote":1,"tweetType":1,"viewCount":2961,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824512245,"gmtCreate":1634338573281,"gmtModify":1634338573281,"author":{"id":"3494524945898080","authorId":"3494524945898080","name":"RyanYe","avatar":"https://static.tigerbbs.com/bbd18b884a4e5ccdb7802012080e0305","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494524945898080","authorIdStr":"3494524945898080"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a>区块链跌，你也跌，区块链涨，你横盘。干","listText":"<a href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a>区块链跌，你也跌，区块链涨，你横盘。干","text":"$SOS Limited(SOS)$区块链跌，你也跌，区块链涨，你横盘。干","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824512245","isVote":1,"tweetType":1,"viewCount":3072,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867614019,"gmtCreate":1633251671898,"gmtModify":1633251671898,"author":{"id":"3494524945898080","authorId":"3494524945898080","name":"RyanYe","avatar":"https://static.tigerbbs.com/bbd18b884a4e5ccdb7802012080e0305","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494524945898080","authorIdStr":"3494524945898080"},"themes":[],"htmlText":"骗子吧，现实宇宙还没搞清楚","listText":"骗子吧，现实宇宙还没搞清楚","text":"骗子吧，现实宇宙还没搞清楚","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867614019","repostId":"1126044283","repostType":4,"isVote":1,"tweetType":1,"viewCount":2820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":885677286,"gmtCreate":1631793187845,"gmtModify":1631793187845,"author":{"id":"3494524945898080","authorId":"3494524945898080","name":"RyanYe","avatar":"https://static.tigerbbs.com/bbd18b884a4e5ccdb7802012080e0305","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494524945898080","authorIdStr":"3494524945898080"},"themes":[],"htmlText":"嘿，真香","listText":"嘿，真香","text":"嘿，真香","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885677286","repostId":"2167651017","repostType":2,"isVote":1,"tweetType":1,"viewCount":3568,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":883068313,"gmtCreate":1631190393232,"gmtModify":1631190393232,"author":{"id":"3494524945898080","authorId":"3494524945898080","name":"RyanYe","avatar":"https://static.tigerbbs.com/bbd18b884a4e5ccdb7802012080e0305","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494524945898080","authorIdStr":"3494524945898080"},"themes":[],"htmlText":"中奖了","listText":"中奖了","text":"中奖了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883068313","repostId":"2166316530","repostType":2,"repost":{"id":"2166316530","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631163354,"share":"https://ttm.financial/m/news/2166316530?lang=&edition=full","pubTime":"2021-09-09 12:55","market":"us","language":"en","title":"U.S. FDA declines emergency use approval for Humanigen's COVID-19 drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2166316530","media":"Reuters","summary":"Sept 9 (Reuters) - The U.S. Food and Drug Administration declined Humanigen Inc's request for emerge","content":"<p>Sept 9 (Reuters) - The U.S. Food and Drug Administration declined Humanigen Inc's request for emergency use authorization of its lenzilumab drug to treat newly hospitalized COVID-19 patients, the company said on Thursday.</p>\n<p>\"In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19,\" the company said in a statement.</p>\n<p>Humanigen expects an ongoing study to provide additional safety and efficacy data to support its new EUA request.</p>\n<p>The company filed its application with the FDA for emergency use of the drug in May, citing late-stage trial data.</p>\n<p>Humanigen also started the process of UK authorization for the drug in June through a rolling review submission.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA declines emergency use approval for Humanigen's COVID-19 drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA declines emergency use approval for Humanigen's COVID-19 drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-09 12:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sept 9 (Reuters) - The U.S. Food and Drug Administration declined Humanigen Inc's request for emergency use authorization of its lenzilumab drug to treat newly hospitalized COVID-19 patients, the company said on Thursday.</p>\n<p>\"In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19,\" the company said in a statement.</p>\n<p>Humanigen expects an ongoing study to provide additional safety and efficacy data to support its new EUA request.</p>\n<p>The company filed its application with the FDA for emergency use of the drug in May, citing late-stage trial data.</p>\n<p>Humanigen also started the process of UK authorization for the drug in June through a rolling review submission.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HGEN":"Humanigen, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166316530","content_text":"Sept 9 (Reuters) - The U.S. Food and Drug Administration declined Humanigen Inc's request for emergency use authorization of its lenzilumab drug to treat newly hospitalized COVID-19 patients, the company said on Thursday.\n\"In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19,\" the company said in a statement.\nHumanigen expects an ongoing study to provide additional safety and efficacy data to support its new EUA request.\nThe company filed its application with the FDA for emergency use of the drug in May, citing late-stage trial data.\nHumanigen also started the process of UK authorization for the drug in June through a rolling review submission.","news_type":1,"symbols_score_info":{"HGEN":0.9}},"isVote":1,"tweetType":1,"viewCount":4447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":812434186,"gmtCreate":1630600681945,"gmtModify":1630600681945,"author":{"id":"3494524945898080","authorId":"3494524945898080","name":"RyanYe","avatar":"https://static.tigerbbs.com/bbd18b884a4e5ccdb7802012080e0305","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494524945898080","authorIdStr":"3494524945898080"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IH\">$洪恩教育(IH)$</a>现在封杀补课，为啥不投快乐教育？","listText":"<a href=\"https://laohu8.com/S/IH\">$洪恩教育(IH)$</a>现在封杀补课，为啥不投快乐教育？","text":"$洪恩教育(IH)$现在封杀补课，为啥不投快乐教育？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812434186","isVote":1,"tweetType":1,"viewCount":4673,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4090986335101910","authorId":"4090986335101910","name":"精神小股民","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"4090986335101910","authorIdStr":"4090986335101910"},"content":"洪恩不算那种外部向孩子输出知识的，而是由孩子产生自主学习兴趣的智能辅助工具，可以说将会迎来封杀培训补课之后的一波红利。因为不让补课，就更要培养孩子自主学习的能力了。只是现在资本市场用脚投票，沾上教育两个字就避之不及，没有深悟其中的逻辑关系。洪恩还是要涨，而且很大可能是翻倍上涨，别着急，耐心持有即可。","text":"洪恩不算那种外部向孩子输出知识的，而是由孩子产生自主学习兴趣的智能辅助工具，可以说将会迎来封杀培训补课之后的一波红利。因为不让补课，就更要培养孩子自主学习的能力了。只是现在资本市场用脚投票，沾上教育两个字就避之不及，没有深悟其中的逻辑关系。洪恩还是要涨，而且很大可能是翻倍上涨，别着急，耐心持有即可。","html":"洪恩不算那种外部向孩子输出知识的，而是由孩子产生自主学习兴趣的智能辅助工具，可以说将会迎来封杀培训补课之后的一波红利。因为不让补课，就更要培养孩子自主学习的能力了。只是现在资本市场用脚投票，沾上教育两个字就避之不及，没有深悟其中的逻辑关系。洪恩还是要涨，而且很大可能是翻倍上涨，别着急，耐心持有即可。"}],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}